The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.

Abstract

We previously developed a prognostic index, SIL, which includes advanced stage (S), soluble interleukin-2 receptor level (I), and elevated lactate dehydrogenase level (L) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (R-CHOP). This time we evaluated the index in a larger cohort and its utility in the risk stratification. The above three factors were independent risk of progression-free survival (PFS). Five-year PFS rates in the standard-risk (SIL index: 0 or 1, n = 367) and high-risk groups (SIL index: 2 or 3, n = 205) were 79% and 53%, respectively (p < 0.0001). When the patients were divided by age (≤60 years and >60 years), the SIL index was a good prognostic indicator for PFS in both groups as well as divided by the number of extranodal involvement site (0-1 and >1). The SIL index is a simple and objective prognostic indicator in DLBCL.

• Authors: Naoto Tomita, Taisei Suzuki, Kazuho Miyashita, Wataru Yamamoto, Kenji Motohashi, Takayoshi Tachibana, Hirotaka Takasaki, Rika Kawasaki, Maki Hagihara, Chizuko Hashimoto, Sachiya Takemura, Hideyuki Koharazawa, Etsuko Yamazaki, Jun Taguchi, Katsumichi Fujimaki, Hiroyuki Fujita, Rika Sakai, Shin Fujisawa, Shigeki Motomura, Keisuke Kawamoto, Hirohito Sone, Jun Takizawa
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 57 Issue 12 Pg. 2763-2770 (12 2016) ISSN: 1029-2403 [Electronic] United States
• PMID: 27320054 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Biomarkers
• R-CHOP protocol
• Receptors, Interleukin-2
• Rituximab
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Lactate Dehydrogenases
• Prednisone

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal, Murine-Derived (adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Biomarkers
• Cyclophosphamide (adverse effects, therapeutic use)
• Doxorubicin (adverse effects, therapeutic use)
• Female
• Humans
• Lactate Dehydrogenases (blood)
• Lymphoma, Large B-Cell, Diffuse (blood, diagnosis, drug therapy, mortality)
• Male
• Middle Aged
• Neoplasm Staging
• Prednisone (adverse effects, therapeutic use)
• Prognosis
• Receptors, Interleukin-2 (blood)
• Rituximab
• Survival Analysis
• Treatment Outcome
• Vincristine (adverse effects, therapeutic use)
• Young Adult